Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vaxcyte ( (PCVX) ) has provided an update.
On December 18, 2025, Vaxcyte amended existing executive change in control and severance agreements for its top executives, following approval by the board’s compensation committee as part of its annual compensation review and planning process. Effective December 31, 2025, the company will increase base salary, bonus and COBRA coverage severance multipliers for CEO Grant Pickering and for President and CFO Andrew Guggenhime, COO Jim Wassil and CTO Harpreet Dhaliwal, both for standard qualifying terminations and for change-in-control-related terminations, in order to bring executive severance levels more in line with market peers and potentially strengthen leadership retention and alignment with shareholder interests.
The most recent analyst rating on (PCVX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Vaxcyte stock, see the PCVX Stock Forecast page.
Spark’s Take on PCVX Stock
According to Spark, TipRanks’ AI Analyst, PCVX is a Neutral.
Vaxcyte’s stock score reflects its position as a development-stage biotech firm with no revenue, high R&D expenses, and reliance on financing. The technical analysis indicates a bearish trend, while valuation metrics show challenges due to negative earnings. However, the company’s robust pipeline and recent positive clinical results provide optimism for the future. The earnings call and corporate events signal potential for growth, but regulatory and financial challenges remain.
To see Spark’s full report on PCVX stock, click here.
More about Vaxcyte
Vaxcyte, Inc. operates in the biopharmaceutical industry, focusing on vaccine development, and is led by a senior executive team including CEO Grant Pickering, President and CFO Andrew Guggenhime, Executive Vice President and COO Jim Wassil, and Chief Technical Operations Officer Harpreet Dhaliwal.
Average Trading Volume: 1,630,916
Technical Sentiment Signal: Hold
Current Market Cap: $5.64B
See more data about PCVX stock on TipRanks’ Stock Analysis page.